266 related articles for article (PubMed ID: 21632857)
21. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
22. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
23. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
[TBL] [Abstract][Full Text] [Related]
24. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.
Bocanegra Gondan AI; Ruiz-de-Angulo A; Zabaleta A; Gómez Blanco N; Cobaleda-Siles BM; García-Granda MJ; Padro D; Llop J; Arnaiz B; Gato M; Escors D; Mareque-Rivas JC
Biomaterials; 2018 Jul; 170():95-115. PubMed ID: 29656235
[TBL] [Abstract][Full Text] [Related]
25. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
26. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
Lim SN; Kuhn S; Hyde E; Ronchese F
J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
[TBL] [Abstract][Full Text] [Related]
27. The fusion protein of HSP65 with tandem repeats of beta-hCG acting as a potent tumor vaccine in suppressing hepatocarcinoma.
Xiangbing H; Yankai Z; Ming L; Yong L; Yu Z; Huiyong Z; Yingying C; Jing H; Yun X; Liang J; Rongyue C; Jingjing L
Int Immunopharmacol; 2010 Feb; 10(2):230-8. PubMed ID: 19913113
[TBL] [Abstract][Full Text] [Related]
28. Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1.
Cho S; Kim SB; Lee Y; Song EC; Kim U; Kim HY; Suh JH; Goughnour PC; Kim Y; Yoon I; Shin NY; Kim D; Kim IK; Kang CY; Jang SY; Kim MH; Kim S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461342
[TBL] [Abstract][Full Text] [Related]
29. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
30. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
Kumar S; Sunagar R; Gosselin E
Front Immunol; 2019; 10():1144. PubMed ID: 31191528
[TBL] [Abstract][Full Text] [Related]
31. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
32. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
33. In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.
Villegas-Mendez A; Garin MI; Pineda-Molina E; Veratti E; Bueren JA; Fender P; Lenormand JL
Mol Ther; 2010 May; 18(5):1046-53. PubMed ID: 20179681
[TBL] [Abstract][Full Text] [Related]
34. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
35. Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation.
Pitoiset F; Vazquez T; Levacher B; Nehar-Belaid D; Dérian N; Vigneron J; Klatzmann D; Bellier B
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794025
[TBL] [Abstract][Full Text] [Related]
36. A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients.
Ciocca DR; Frayssinet P; Cuello-Carrión FD
Cell Stress Chaperones; 2007; 12(1):33-43. PubMed ID: 17441505
[TBL] [Abstract][Full Text] [Related]
37. Human chorionic gonadotropin as a target for cancer vaccines.
Triozzi PL; Stevens VC
Oncol Rep; 1999; 6(1):7-17. PubMed ID: 9864394
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
Jin JW; Tang SQ; Rong MZ; Zhang MQ
Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
[TBL] [Abstract][Full Text] [Related]
39. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis.
Ruffini PA; Biragyn A; Coscia M; Harvey LK; Cha SC; Bogen B; Kwak LW
J Leukoc Biol; 2004 Jul; 76(1):77-85. PubMed ID: 15075363
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis.
Yin X; Wang W; Zhu X; Wang Y; Wu S; Wang Z; Wang L; Du Z; Gao J; Yu J
Biochem Biophys Res Commun; 2015 Sep; 465(2):239-44. PubMed ID: 26253468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
